Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial-Reference-Cited by-同舟云学术

Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial

Published:2024-08-21 Issue:1 Volume:14 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Cavallaro Gianluca,Grassi Anna,Pavoni Chiara,Micò Maria Caterina,Busca Alessandro,Cavattoni Irene Maria,Santarone Stella^ORCID,Borghero Carlo,Olivieri Attilio,Milone Giuseppe^ORCID,Chiusolo Patrizia^ORCID,Musto Pellegrino^ORCID,Saccardi Riccardo,Patriarca Francesca,Pane Fabrizio,Saporiti Giorgia,Rivela Paolo^ORCID,Terruzzi Elisabetta,Cerretti Raffaella^ORCID,Marotta Giuseppe,Carella Angelo Michele,Nagler Arnon,Russo Domenico,Corradini Paolo^ORCID,Bernasconi Paolo,Iori Anna Paola,Castagna Luca,Mordini Nicola,Oldani Elena,Di Grazia Carmen,Bacigalupo Andrea,Rambaldi Alessandro^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41408-024-01116-5.pdf

Reference26 articles.

1. D’Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2020;26:e177–82.

2. Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016;127:62–70.

3. Heinicke T, Krahl R, Kahl C, Cross M, Scholl S, Wolf HH, et al. Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials. Ann Hematol. 2021;100:2387–98.

4. Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus cy as conditioning regimen—a report from the acute leukemia working. J Clin Oncol. 2013;31:3549–56.

5. Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013;122:3863–70.